Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

PARP inhibition induces enrichment of DNA repair proficient CD133 and CD117 positive ovarian cancer stem cells.

Bellio C, DiGloria C, Foster R, James K, Konstantinopoulos PA, Growdon WB, Rueda BR.

Mol Cancer Res. 2018 Nov 6. pii: molcanres.0594.2018. doi: 10.1158/1541-7786.MCR-18-0594. [Epub ahead of print]

PMID:
30401718
2.

Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?

Manning-Geist BL, Hicks-Courant K, Gockley AA, Clark RM, Del Carmen MG, Growdon WB, Horowitz NS, Berkowitz RS, Muto MG, Worley MJ Jr.

Gynecol Oncol. 2018 Aug;150(2):233-238. doi: 10.1016/j.ygyno.2018.06.015. Epub 2018 Jun 20.

PMID:
29933927
3.

Treatment of ovarian cancer by targeting the tumor stem cell-associated carbohydrate antigen, Sialyl-Thomsen-nouveau.

Starbuck K, Al-Alem L, Eavarone DA, Hernandez SF, Bellio C, Prendergast JM, Stein J, Dransfield DT, Zarrella B, Growdon WB, Behrens J, Foster R, Rueda BR.

Oncotarget. 2018 May 1;9(33):23289-23305. doi: 10.18632/oncotarget.25289. eCollection 2018 May 1.

4.

Assessment of treatment factors and clinical outcomes in cervical cancer in older women compared to women under 65 years old.

Diver EJ, Hinchcliff EM, Gockley AA, Melamed A, Contrino L, Feldman S, Growdon WB.

J Geriatr Oncol. 2018 Sep;9(5):516-519. doi: 10.1016/j.jgo.2018.02.004. Epub 2018 Mar 2.

PMID:
29503115
5.

Patterns of palliative care referral in ovarian cancer: A single institution 5 year retrospective analysis.

Nitecki R, Diver EJ, Kamdar MM, Boruta DM 2nd, Del Carmen MC, Clark RM, Goodman A, Schorge JO, Growdon WB.

Gynecol Oncol. 2018 Mar;148(3):521-526. doi: 10.1016/j.ygyno.2018.01.018. Epub 2018 Feb 12.

PMID:
29395315
6.

Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.

Melamed A, Nitecki R, Boruta DM 2nd, Del Carmen MG, Clark RM, Growdon WB, Goodman A, Schorge JO, Rauh-Hain JA.

Obstet Gynecol. 2017 May;129(5):861-869. doi: 10.1097/AOG.0000000000001851.

PMID:
28383367
7.

Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.

Bregar A, Deshpande A, Grange C, Zi T, Stall J, Hirsch H, Reeves J, Sathyanarayanan S, Growdon WB, Rueda BR.

Gynecol Oncol. 2017 Jun;145(3):446-452. doi: 10.1016/j.ygyno.2017.03.006. Epub 2017 Mar 25.

8.

Patient, treatment and discharge factors associated with hospital readmission within 30days after surgery for vulvar cancer.

Dorney KM, Growdon WB, Clemmer J, Rauh-Hain JA, Hall TR, Diver E, Boruta D, Del Carmen MG, Goodman A, Schorge JO, Horowitz N, Clark RM.

Gynecol Oncol. 2017 Jan;144(1):136-139. doi: 10.1016/j.ygyno.2016.11.009. Epub 2016 Nov 8.

PMID:
27836203
9.

Management and outcome of cervical cancer diagnosed in pregnancy.

Bigelow CA, Horowitz NS, Goodman A, Growdon WB, Del Carmen M, Kaimal AJ.

Am J Obstet Gynecol. 2017 Mar;216(3):276.e1-276.e6. doi: 10.1016/j.ajog.2016.10.034. Epub 2016 Oct 31.

PMID:
27810552
10.

Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.

Garrett LA, Growdon WB, Rueda BR, Foster R.

J Ovarian Res. 2016 Sep 15;9(1):58. doi: 10.1186/s13048-016-0267-2.

11.

Timing of Referral to the New England Trophoblastic Disease Center: Does Referral with Molar Pregnancy Versus Postmolar Gestational Trophoblastic Neoplasia Affect Outcomes?

Diver EJ, Horowitz NS, Goldstein DP, Bernstein M, Berkowitz RS, Growdon WB.

J Reprod Med. 2016 May-Jun;61(5-6):187-91.

PMID:
27424356
12.

Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation.

Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB.

Gynecol Oncol. 2016 Jun;141(3):570-579. doi: 10.1016/j.ygyno.2016.03.027. Epub 2016 Apr 1.

PMID:
27017985
13.

A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer.

Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ.

Gynecol Oncol. 2016 Apr;141(1):108-12. doi: 10.1016/j.ygyno.2016.02.032.

PMID:
27016236
14.

Predictors of 30-day readmission following hysterectomy for benign and malignant indications at a tertiary care academic medical center.

Lee MS, Venkatesh KK, Growdon WB, Ecker JL, York-Best CM.

Am J Obstet Gynecol. 2016 May;214(5):607.e1-607.e12. doi: 10.1016/j.ajog.2015.11.037. Epub 2015 Dec 15.

PMID:
26704895
15.

Emerging strategies for targeting PI3K in gynecologic cancer.

Bregar AJ, Growdon WB.

Gynecol Oncol. 2016 Feb;140(2):333-44. doi: 10.1016/j.ygyno.2015.09.083. Epub 2015 Sep 30. Review.

PMID:
26432040
16.

Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR).

Dong F, Kojiro S, Borger DR, Growdon WB, Oliva E.

Am J Surg Pathol. 2015 Aug;39(8):1045-53. doi: 10.1097/PAS.0000000000000454.

PMID:
26171917
17.

The Therapeutic Challenge of Targeting HER2 in Endometrial Cancer.

Diver EJ, Foster R, Rueda BR, Growdon WB.

Oncologist. 2015 Sep;20(9):1058-68. doi: 10.1634/theoncologist.2015-0149. Epub 2015 Jun 22. Review.

18.

Comparing mortality of vaginal sarcoma, squamous cell carcinoma, and adenocarcinoma in the surveillance, epidemiology, and end results database.

Ghezelayagh T, Rauh-Hain JA, Growdon WB.

Obstet Gynecol. 2015 Jun;125(6):1353-61. doi: 10.1097/AOG.0000000000000861.

PMID:
26000506
19.

Delay in chemotherapy administration impacts survival in elderly patients with epithelial ovarian cancer.

Joseph N, Clark RM, Dizon DS, Lee MS, Goodman A, Boruta D Jr, Schorge JO, Del Carmen MG, Growdon WB.

Gynecol Oncol. 2015 Jun;137(3):401-5. doi: 10.1016/j.ygyno.2015.03.052. Epub 2015 Apr 1.

PMID:
25839911
20.

Gynecologic Oncologist as surgical consultant: intraoperative consultations during general gynecologic surgery as an important focus of gynecologic oncology training.

Aviki EM, Rauh-Hain JA, Clark RM, Hall TR, Berkowitz LR, Boruta DM, Growdon WB, Schorge JO, Goodman A.

Gynecol Oncol. 2015 Apr;137(1):93-7. doi: 10.1016/j.ygyno.2015.01.536. Epub 2015 Jan 21.

PMID:
25617772
21.

HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant.

Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR.

Gynecol Oncol. 2015 Apr;137(1):160-6. doi: 10.1016/j.ygyno.2015.01.533. Epub 2015 Jan 17.

22.

Feasibility and surgical outcome in obese versus nonobese patients undergoing laparoendoscopic single-site hysterectomy: a multicenter case-control study.

Fanfani F, Boruta DM, Fader AN, Vizza E, Growdon WB, Kushnir CL, Corrado G, Scambia G, Turco LC, Fagotti A.

J Minim Invasive Gynecol. 2015 Mar-Apr;22(3):456-61. doi: 10.1016/j.jmig.2014.12.008. Epub 2014 Dec 12.

PMID:
25510981
23.

Surgical Apgar Score and prediction of morbidity in women undergoing hysterectomy for malignancy.

Clark RM, Lee MS, Alejandro Rauh-Hain J, Hall T, Boruta DM, del Carmen MG, Goodman A, Schorge JO, Growdon WB.

Gynecol Oncol. 2015 Mar;136(3):516-20. doi: 10.1016/j.ygyno.2014.11.016. Epub 2014 Dec 2.

PMID:
25475542
24.

Notch signaling in serous ovarian cancer.

Groeneweg JW, Foster R, Growdon WB, Verheijen RH, Rueda BR.

J Ovarian Res. 2014 Nov 4;7:95. doi: 10.1186/s13048-014-0095-1. Review.

25.

Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.

Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB.

Clin Cancer Res. 2014 Dec 15;20(24):6517-6528. doi: 10.1158/1078-0432.CCR-14-1647. Epub 2014 Oct 7.

26.

The N-methyl-D-aspartate receptor, a precursor to N-methyl-D-aspartate receptor encephalitis, is found in the squamous tissue of ovarian teratomas.

Clark RM, Lynch MP, Kolp R, Zukerberg LR, Growdon WB, Rueda BR.

Int J Gynecol Pathol. 2014 Nov;33(6):598-606. doi: 10.1097/PGP.0000000000000104.

PMID:
25272299
27.

Inhibition of notch signaling in combination with Paclitaxel reduces platinum-resistant ovarian tumor growth.

Groeneweg JW, DiGloria CM, Yuan J, Richardson WS, Growdon WB, Sathyanarayanan S, Foster R, Rueda BR.

Front Oncol. 2014 Jul 7;4:171. doi: 10.3389/fonc.2014.00171. eCollection 2014.

28.

Intraoperative Radiation Therapy in the Management of Gynecologic Malignancies.

Foley OW, Rauh-Hain JA, Clark RM, Goodman A, Growdon WB, Boruta DM, Schorge JO, Del Carmen MG.

Am J Clin Oncol. 2016 Aug;39(4):329-34. doi: 10.1097/COC.0000000000000063.

PMID:
24685883
29.

Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.

Groeneweg JW, Hall TR, Zhang L, Kim M, Byron VF, Tambouret R, Sathayanrayanan S, Foster R, Rueda BR, Growdon WB.

Gynecol Oncol. 2014 Jun;133(3):607-15. doi: 10.1016/j.ygyno.2014.03.560. Epub 2014 Mar 22.

PMID:
24667249
30.

Management and outcomes for elderly women with vulvar cancer over time.

Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Dizon DS, Schorge JO, del Carmen MG.

BJOG. 2014 May;121(6):719-27; discussion 727. doi: 10.1111/1471-0528.12580. Epub 2014 Feb 24.

31.

Endometriosis-associated ovarian malignancy: a retrospective analysis of presentation, treatment, and outcome.

Garrett LA, Growdon WB, Goodman A, Boruta DM, Schorge JO, del Carmen MG.

J Reprod Med. 2013 Nov-Dec;58(11-12):469-76.

PMID:
24568040
32.

Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.

Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR.

Gynecol Oncol. 2014 May;133(2):346-52. doi: 10.1016/j.ygyno.2014.02.022. Epub 2014 Feb 19.

PMID:
24561032
33.

Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis.

Vargas R, Rauh-Hain JA, Clemmer J, Clark RM, Goodman A, Growdon WB, Schorge JO, Del Carmen MG, Horowitz NS, Boruta DM 2nd.

Gynecol Oncol. 2014 May;133(2):216-20. doi: 10.1016/j.ygyno.2014.02.011. Epub 2014 Feb 16.

PMID:
24548726
34.

Transitional cell carcinoma of the ovary: a case-control study.

Guseh SH, Rauh-Hain JA, Tambouret RH, Davis M, Clark RM, Boruta DM, Goodman A, Growdon WB, Schorge JO, del Carmen MG.

Gynecol Oncol. 2014 Mar;132(3):649-53. doi: 10.1016/j.ygyno.2014.01.020. Epub 2014 Jan 21.

PMID:
24462804
35.

Mucinous Adenocarcinoma of the Endometrium Compared With Endometrioid Endometrial Cancer: A SEER Analysis.

Rauh-Hain JA, Vargas RJ, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG.

Am J Clin Oncol. 2016 Feb;39(1):43-8. doi: 10.1097/COC.0000000000000015.

PMID:
24390270
36.

Identification of LMX1B as a novel oncogene in human ovarian cancer.

He L, Guo L, Vathipadiekal V, Sergent PA, Growdon WB, Engler DA, Rueda BR, Birrer MJ, Orsulic S, Mohapatra G.

Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.

PMID:
24056967
37.

Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.

Rauh-Hain JA, Davis M, Clemmer J, Clark RM, Growdon WB, Goodman AK, Boruta DM 2nd, Schorge JO, del Carmen MG.

Gynecol Oncol. 2013 Nov;131(2):404-9. doi: 10.1016/j.ygyno.2013.08.029. Epub 2013 Sep 1.

PMID:
24004647
38.

Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer.

Rauh-Hain JA, Guseh SH, Esselen KM, Growdon WB, Schorge JO, Horowitz NS, Krasner CN, del Carmen MG, Birrer MJ, Dizon DS.

Int J Gynecol Cancer. 2013 Sep;23(7):1219-25. doi: 10.1097/IGC.0b013e31829f17c9.

PMID:
23975042
39.

Racial disparities in cervical cancer survival over time.

Rauh-Hain JA, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG.

Cancer. 2013 Oct 15;119(20):3644-52. doi: 10.1002/cncr.28261. Epub 2013 Jul 31.

40.

Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis.

Rauh-Hain JA, Diver EJ, Clemmer JT, Bradford LS, Clark RM, Growdon WB, Goodman AK, Boruta DM 2nd, Schorge JO, del Carmen MG.

Gynecol Oncol. 2013 Oct;131(1):46-51. doi: 10.1016/j.ygyno.2013.07.097. Epub 2013 Jul 29.

PMID:
23906658
41.

Racial disparities and changes in clinical characteristics and survival for vulvar cancer over time.

Rauh-Hain JA, Clemmer J, Clark RM, Bradford LS, Growdon WB, Goodman A, Boruta DM 2nd, Schorge JO, del Carmen MG.

Am J Obstet Gynecol. 2013 Nov;209(5):468.e1-468.e10. doi: 10.1016/j.ajog.2013.07.021. Epub 2013 Jul 24.

PMID:
23891626
42.

Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma.

Clark RM, Growdon WB, Wiechert A, Boruta D, Del Carmen M, Goodman AK, Bradford L, Rauh-Hain A, Schorge JO.

Gynecol Oncol. 2013 Sep;130(3):407-10. doi: 10.1016/j.ygyno.2013.05.034. Epub 2013 Jun 5.

PMID:
23747329
43.

Prognostic factors associated with time to hCG remission in patients with low-risk postmolar gestational trophoblastic neoplasia.

Maestá I, Growdon WB, Goldstein DP, Bernstein MR, Horowitz NS, Rudge MV, Berkowitz RS.

Gynecol Oncol. 2013 Aug;130(2):312-6. doi: 10.1016/j.ygyno.2013.05.017. Epub 2013 May 23.

PMID:
23707672
44.

Case records of the Massachusetts General Hospital. Case 14-2013. A 70-year-old woman with vaginal bleeding.

Penson RT, Goodman A, Growdon WB, Borger DR, Lee SI, Oliva E.

N Engl J Med. 2013 May 9;368(19):1827-35. doi: 10.1056/NEJMcpc1209276. No abstract available.

PMID:
23656649
45.

The role of para-aortic lymphadenectomy in the surgical staging of women with intermediate and high-risk endometrial adenocarcinomas.

May T, Shoni M, Vitonis AF, Quick CM, Growdon WB, Muto MG.

Int J Surg Oncol. 2013;2013:858916. doi: 10.1155/2013/858916. Epub 2013 Feb 27.

46.

Influence of hydatidiform mole follow-up setting on postmolar gestational trophoblastic neoplasia outcomes: a cohort study.

Dantas PR, Maestá I, Cortés-Charry R, Growdon WB, Braga A, Rudge MV, Berkowitz RS.

J Reprod Med. 2012 Jul-Aug;57(7-8):305-9.

PMID:
22838246
47.

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva.

Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS.

Gynecol Oncol. 2012 Oct;127(1):141-6. doi: 10.1016/j.ygyno.2012.06.028. Epub 2012 Jun 26.

PMID:
22750258
48.

Gestational trophoblastic neoplasia in adolescents.

Rauh-Hain JA, Growdon WB, Braga A, Goldstein DP, Berkowitz RS.

J Reprod Med. 2012 May-Jun;57(5-6):237-42.

PMID:
22696819
49.

Molar pregnancy in adolescents.

Braga A, Growdon WB, Bernstein M, Maestá I, Rudge MV, Goldstein DP, Berkowitz RS.

J Reprod Med. 2012 May-Jun;57(5-6):225-30.

PMID:
22696817
50.

Prognostic determinants in patients with uterine and ovarian clear carcinoma.

Rauh-Hain JA, Winograd D, Growdon WB, Schorge JO, Goodman AK, Boruta DM, Berkowitz RS, Horowitz NS, Del Carmen MG.

Gynecol Oncol. 2012 May;125(2):376-80. doi: 10.1016/j.ygyno.2012.02.016. Epub 2012 Feb 21.

PMID:
22366593

Supplemental Content

Loading ...
Support Center